203 related articles for article (PubMed ID: 17947727)
1. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
4. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Pintova S; Dharmupari S; Moshier E; Zubizarreta N; Ang C; Holcombe RF
Cancer Chemother Pharmacol; 2019 Sep; 84(3):591-598. PubMed ID: 31203390
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
14. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
[TBL] [Abstract][Full Text] [Related]
15. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
[TBL] [Abstract][Full Text] [Related]
17. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
18. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
O'Reilly EM; Niedzwiecki D; Hall M; Hollis D; Bekaii-Saab T; Pluard T; Douglas K; Abou-Alfa GK; Kindler HL; Schilsky RL; Goldberg RM;
Oncologist; 2010; 15(12):1310-9. PubMed ID: 21148613
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of sunitinib in patients with metastatic urothelial cancer.
Gallagher DJ; Milowsky MI; Gerst SR; Ishill N; Riches J; Regazzi A; Boyle MG; Trout A; Flaherty AM; Bajorin DF
J Clin Oncol; 2010 Mar; 28(8):1373-9. PubMed ID: 20142593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]